How do you approach chemotherapy use in patients with locally advanced ER+/HER2 negative patients with cirrhosis and platelets < 100K?

This is fortunately a rare situation encountered in breast cancer patients but in those situations it poses a challenging problem. In general, I look at this as two categories: In patients with compensated cirrhosis (with Child-Pugh score less than 7 and no clinically detectable ascites), the mortal...